Nucleic acids therapeutics using chemical modified oligonucleotides

Abstract

Both antisense oligonucleotides and aptamers that suppress mRNA expression and inhibit protein function are in market in US as Nucleic acids therapeutics (NAT). Furthermore, many candidates are in clinical trials. NAT are paid attention as novel modality because NAT can address molecules that have been undruggable with conventional therapeutics such as antibodies and small molecules. In this review, I describe properties of chemical modification for oligonucleotides and the NAT business with their oligonucleotides.